highly variable drugs-Cmax [Regulatives / Guidelines]

posted by nuka2020 – United Arab Emirates, 2020-11-19 12:09 (1341 d 15:36 ago) – Posting: # 22067
Views: 2,647

According to the GCC guidelines a wider range of Cmax(i.e 75-133%) can be acceptable for HVDP, where it has been demonstrated that the within- subject variability for Cmax of the reference compound in the study is >30%.
But, i have a study which was performed as per Eu guidelines and accordingly, the acceptance criteria for Cmax can be widened to a maximum of 69.84 – 143.19%. Accordingly, the results of Cmax is: 70.46%-141.90%
Need suggestion whether this studies can be acceptable as per GCC guidelines?? :confused::confused:

Complete thread:

UA Flag
Activity
 Admin contact
23,113 posts in 4,858 threads, 1,644 registered users;
35 visitors (0 registered, 35 guests [including 11 identified bots]).
Forum time: 04:45 CEST (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5